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Apamin, a peptide component of bee venom (BV), has anti-inﬂammatory properties. However, the molecular mechanisms by
which apamin prevents atherosclerosis are not fully understood. We examined the eﬀect of apamin on atherosclerotic mice.
Atherosclerotic mice received intraperitoneal (ip) injections of lipopolysaccharide (LPS, 2mg/kg) to induce atherosclerotic change
andwerefedanatherogenicdietfor12weeks.Apamin(0.05mg/kg)wasadministeredbyipinjection.LPS-inducedTHP-1-derived
macrophage inﬂammation treated with apamin reduced expression of tumor necrosis factor (TNF)-α, vascular cell adhesion
molecule (VCAM)-1, and intracellular cell adhesion molecule (ICAM)-1, as well as the nuclear factor kappa B (NF-κB) signaling
pathway.Apamindecreasedtheformationofatheroscleroticlesionsasassessedbyhematoxylinandelasticstaining.Treatmentwith
apamin reduced lipids, Ca2+ levels, and TNF-α in the serum from atherosclerotic mice. Further, apamin signiﬁcantly attenuated
expression of VCAM-1, ICAM-1, TGF-β1, and ﬁbronectin in the descending aorta from atherosclerotic mice. These results
indicate that apamin plays an important role in monocyte/macrophage inﬂammatory processing and may be of potential value for
preventing atherosclerosis.
1.Introduction
Atherosclerosis is a progressive disease characterized by
formation of a plaque, consisting mainly of cholesterol,
other lipids, and debris from cellular death, in the inner
lining of arteries [1]. It is increasingly regarded as a
chronic inﬂammatory disease of the vessel wall [1]. Many
macrophages can be observed in atherosclerotic lesions,
and early lesions of atherosclerosis are characterized by
the inﬁltration of monocytes/macrophages, proliferation of
medial smooth muscle cells, and the presence of macrophage
foam cells [2]. Therefore, the number of macrophages
in lesions is an important measure of an atherosclerotic
plaque.
Macrophages are multipotent inﬂammatory cells with
the capacity to synthesize and secrete proinﬂammatory
cytokines, such as tumor necrosis factor (TNF)-α, inter-
leukin(IL)-1β,IL-8,andIL-6[3].Thesecytokinesplayacen-
tral role during development of atherosclerosis. Proinﬂam-
matory cytokines are regulated at the transcriptional levels
by several transcription factors, including activator protein
(AP)-1 and nuclear factor-kappa B (NF-κB) [4, 5]. NF-κBi s
atranscription factorthatplaysakey roleintheregulationof
host immune and inﬂammatory responses by increasing the
expression of gene encoding cytokines, chemokines, growth
factors, cell adhesion molecules, and several acute phase
proteins [6]. NF-κBa ﬀects diﬀerent steps in the atheroscle-
roticprocess,includinginitiationofatherosclerosis,foamcell
formation, proliferation of smooth muscle cells, and ﬁbrous
cap formation [7]. Proinﬂammatory cytokines and adhesion
molecules, such as vascular cell adhesion molecule (VCAM)-
1 and intercellular cell adhesion molecule (ICAM)-1, induce2 Evidence-Based Complementary and Alternative Medicine
atherosclerosis by NF-κBa c t i v a t i o n[ 8, 9]. Cytoplasmic
dissociation of NF-κB from inhibitor of κB( I κB) is regulated
by activation of IκB inhibitor complex (IKK). Activated
IKK phosphorylates IκBα,w h i c hf r e e sN F - κB dimers to
translocate to the nucleus. NF-κB then interacts with κB
elements in the promoter region of several inﬂammatory
genes to activate their transcription [10]. Potent inhibitors
of IKKs that prevent NF-κB activity through blockage of IκB
release can be useful for treatment of inﬂammatory diseases
[11,12].Therefore,inhibitingtranscriptionfactorsrelatedto
the activation of inﬂammation is a good biological target for
anti-inﬂammatory activity.
Apamin is an integral part of bee venom (BV), com-
prising about 2-3% of its dry weight [13]. BV from the
honeybee (Apis mellifera) has been traditionally used in
China, Korea, and Japan for arthritis, bursitis, back pain,
rheumatism, skin disease, and other chronic conditions. BV
contains a variety of peptides including melittin, apamin,
adolapin, and master cell degranulating peptide. It also
contains enzymes, biological amines, and nonpeptide com-
ponents [14]. It would be interesting to show that apamin
in BV is responsible for altering transcription expression
of proinﬂammatory cytokines, although the mechanisms
behind that regulation remain unclear. Apamin has long
been known as a highly selective blocker of Ca2+-activated
K+ channels [15] .S e v e r a ls t u d i e sh a v ec o n ﬁ r m e dt h a ts o m e
calcium channel blockers can decrease areas of atheroscle-
rotic lesions, production of oxidative stress, and expression
of inﬂammatory cytokines without conspicuously eﬀecting
blood lipid levels [16]. However, the molecular mechanisms
of the anti-atherosclerotic eﬀects of apamin have not been
elucidated. To gain a better insight into these mechanisms,
the aim of this study is to evaluate the anti-atherosclerotic
mechanisms of apamin in THP-1-derived macrophages and
to investigate the anti-atherosclerotic eﬀects of apamin in
mouse models of atherosclerosis.
2.MaterialsandMethods
2.1. Cell Culture. The human monocytic cell line THP-1
was obtained from the American Type Culture Collection
and cultured in with RPMI-1640 medium supplemented
with 10% fetal bovine serum and 1% antibiotics. Cells
were cultured in humidiﬁed incubator at 37◦Ci na5 %
CO2 atmosphere. THP-1 cells (1 × 106 cells/mL) were
diﬀerentiated into macrophages with the use of 50nM
phorbol-12-myristate-13-acetate for 48h. For macrophage
inﬂammation, cells incubated in serum-free culture medium
prior to treatment with apamin (0.5, 1, 2μg/mL, Sigma,
MO, USA) for 6h. After this incubation with apamin, THP-
1-derived macrophages were activated with LPS (1μg/mL,
Sigma, MO, USA) for 24h.
2.2. Enzyme-Linked Immunosorbent Assay (ELISA). Con-
centrations of TNF-α in culture supernatant and serum
were measured with a solid-phase sandwich ELISA using a
quantikine human or mouse TNF-α kit (R&D Systems, MN,
USA). The absorbance was measured at 450nm in an ELISA
reader (BMG labtechnologies, Mornington, Germany).
2.3.WesternBlotAnalysis. Cellsortissueswerehomogenized
in a lysis buﬀer (50mM Tris pH 8.0, 150mM NaCl, 5mM
EDTA, 0.5% NP-40, 100mM PMSF, 1M DTT, 10mg/mL
leupeptin, and aprotinin; all from Sigma, MO, USA). For
cytosolic fractions, cells were suspended in extraction buﬀer
(10mM HEPES pH 8.0, 1.5mM MgCl2,1 0m MK C l ,0 . 5m M
DTT, 300mM sucrose, 0.1% NP-40, and 0.5mM PMSF) for
15min on ice and were centrifuged 6000×g for 15min.
The supernatant from this step is the cytosolic fraction,
and the pellet is the nuclear fraction. The nuclear fractions
were collected by diﬀerent extraction buﬀer (20mM HEPES
pH 8.0, 20% glycerol, 100mM KCl, 100mM NaCl, 0.2mM
EDTA, 0.5mM PMSF, and 0.5mM DTT) for 15min on ice.
The nuclear fractions were centrifuged 12000×gf o r1 0m i n
at 4◦C to remove insoluble protein. Then, protein concentra-
tion was determined using the Bradford assay. Total protein
was separated on 10% to 12% SDS-polyacrylamide gels and
transferred to polyvinylidene ﬂuoride membrane (Millipore,
MA, USA). Membranes were blocked in 5% skim milk for
1h at room temperature. Protein samples were incubated
with primary antibodies for 3h. Primary antibodies used
in this study were the following: anti-VCAM-1, anti-ICAM-
1, and anti-TGF-β1 were obtained from R&D Systems
(MN, USA); anti-IKK, anti-phospho-IKK, anti-IκBα, anti-
phospho-IκBα, anti-NF-κB p65 and anti-phospho-NF-κB
p65 were purchased from Cell Signaling Technology (MA,
USA); anti-ﬁbronectin and anti-F4/80 were obtained from
Abcam (MA, USA), anti-glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and histone H2B were purchased
from Santa Cruz (CA, USA). The membranes probed with
a horseradish peroxidase (HRPO)-conjugated secondary
antibodied were used for detection. Target proteins were
detected using an enhanced chemiluminescence detection
system (Amersham, NJ, USA) and ﬁlm.
2.4. Electrophoretic Mobility Shift Assay (EMSA). AD I G
Gel shift kit (Roche, Mannheim, Germany) was used for
EMSA assays. The NF-κB oligonucleotide probe (5 -CTT
GAA GGG ATT TCC CTG GCT TGA AGG GAT TTC
CCT GG-3 ; only sense strands are shown) was end-labeled
with DIG-ddUTP. For binding reaction, 9μg nuclear extract
protein was mixed with binding buﬀer (0.5μg poly dI-dC,
0.1μg poly L-lysine, and 0.8μg labeled oligonucleotide, ﬁnal
volume of 20μL) and was incubated at 37◦C for 30min. The
nuclear protein-DNA complex was separated by 6% non-
denaturing polyacrylamide gel in TBE buﬀer (22.5mM Tris,
2 2 . 5 m Mb o r i ca c i d ,0 . 5 m ME D T A ,a n dp H8 . 3 )a t8 0 V
for 1.5–2h at 4◦C. Samples were transferred to Hybond-
XL membranes (Amersham Biosciences, Amersham, UK)
for 30min and crosslinked for 10min under ultraviolet
light. Membrane was incubated with anti-digoxigenin-AP
Fab fragments (1:10,000) for 30min, and the nuclear
protein-DNA bands were developed with detection solu-
tion including 100mM Tris-HCl, 100mM NaCl, pH 9.5,Evidence-Based Complementary and Alternative Medicine 3
and 100μg/mL disodium 3-[4-metoxyspiro {1,2-dioxetane-
3,2 (5 -chloro)tricyclo(3.3.1.13,7)decan}-4-yl] phenyl phos-
phate.
2.5. NF-κB Promoter Activity Assay. Reporter gene activity
was evaluated by cell-based analysis methods for assaying
NF-κBa c t i v i t y .N F - κBp r o m o t e r - l u c i f e r a s ec o n s t r u c tw a s
transiently transfected by using transfection reagent lipo-
fectamine 2000 (Invitrogen, CA, USA). After harvesting,
cells were lysed in reporter lysis buﬀer (Promega, WI,
USA), cell extract (50μg/20μL) was mixed with 100μL
of luciferase assay reagent, and the emitted light intensity
was measured using luminometer FLUOstar OPIMA (BMG
Labtech, Germany). The luciferase activity was represented
as the fold induction compared with normal control cells.
2.6.ExperimentalAnimals. MaleC57BL/6mice(8weeksold,
20–25g) were obtained from Samtako (Osan, Republic of
Korea) and were allowed one week for stabilization. Mice
were kept in a room maintained at 21–25◦Cu n d e r1 2 h
dark/light cycles. The animal experiments were performed
in accordance with the NIH guidelines for the care and use
of laboratory animals. Mice were randomly subdivided into
four groups (n = 10/group) and were maintained under
various conditions for 12 weeks. The normal control (NC)
group was fed with chow diet (Samyang Feed, Daejeon,
Republic of Korea). The apamin (Apa) group was fed with
chow diet and ip injected with 0.05mg/kg apamin (Sigma,
MO, USA) twice a week. The LPS/fat group (atherosclerotic
mice) was fed with an atherogenic diet (1.25% cholesterol,
15% fat, and 0.5% cholic acid) and ip injected with 2mg/kg
LPS (Sigma, MO, USA) three times a week. The LPS/fat+Apa
group was atherosclerotic mice treated with 0.05mg/kg
apamin twice a week.
2.7. Biochemical Analysis. Blood was collected from inferior
vena cava and immediately centrifuged at 8000×gf o r
10min at 4◦C to separate serum. Serum total cholesterol
(TC) and triglycerides (TG) were measured using a com-
mercial kit (Asan, Hwaseong, Republic of Korea). Serum
Ca2+ accumulation was measured using a commercial kit
(BioAssay Systems, CA, USA). The concentration of Ca2+
accumulation was determined with reference to a standard
curve constructed with each assay, and mean plus standard
deviation was calculated.
2.8. Reverse-Transcription Polymerase Chain Reaction (RT-
PCR). Total RNA was isolated from the aorta with TRIzol
Reagent (Gibco, NY, USA) according to manufacturer’s
recommendations. RNA (0.5μg) was reverse-transcribed
using M-MLV reverse transcriptase (Promega, WI, USA).
Single-stranded cDNA was ampliﬁed by PCR with primers
(Bioneer, Daejeon, Republic of Korea) speciﬁc to mouse
VCAM-1, ICAM-1, TGF-β1, ﬁbronectin, and GAPDH used
as a positive control. Primer sequences are the following:
ICAM-1 sense: 5 -AGC ACC TCC CCA CCT ACT TT-3 ;
ICAM-1 antisense: 5 -AGC TTG CAC GAC CCT TCT AA-
3 ;V C A M - 1s e n s e :5  -TAC CAG CTC CCA AAA TCC TG-3 ;
VCAM-1 antisense: 5 -TCT GCT AAT TCC AGC CTC GT-
3 ;T G F - β1s e n s e :5  -CCT GCT GCT TTC TCC CTC AAC
C-3 ;T G F - β1 antisense: 5 -CTG GCA CTG CTT CCC GAA
TGT C-3 ;ﬁ b r o n e c t i ns e n s e :5  -TGT GAC AAC TGC CGT
AGA CC-3 ; ﬁbronectin antisense: 5 -GAC CAA CTG TCA
CCA TTG AGG-3 ; GAPDH sense: 5 -GTG GAC ATT GTT
GCC ATC AAC G-3 ; GAPDH antisense: 5 -GAG GGA GTT
GTC ATA TTT CTC G-3 . PCR products were visualized by
2% agarose gel. The band intensity was quantiﬁed by using
Image Analysis (Las 3000, Fuji, Japan).
2.9. Histological Analysis. All aorta specimens were ﬁxed
overnightin10%formalinsolution,dehydrated,andembed-
d e di np a r a ﬃn. Thin sections were mounted on glass slides,
dewaxed, rehydrated in distilled water, and stained with
hematoxylin and eosin (H&E) and Verhoeﬀ’ elastic tissue
staining solution (alcoholichematoxylin, 10% ferric chloride
and iodine solution). For immunohistochemistry, sections
were incubated with anti-ICAM-1 (R&D Systems, MA,
USA) and anti-F4/80 (Abcam, MA, USA) for 1h at 37◦C.
Signals were visualized using an Envision system (DAKO,
CA, USA) for 30min at 37◦C. DAB (3,3 -diaminobenzidine
tetrahydrochloride) was used as the coloring reagent, and
hematoxylin was used as counterstain. For immunoﬂuores-
cencestaining,aortasectionswereincubatedwithanti-F4/80
(Abcam, MA, USA) and anti-mouse biotinylated secondary
antibodies conjugated with FITC (Jackson ImmunoResearch
Laboratories, PA, USA). Slides were mounted using VEC-
TASHIELD Mounting Medium (VECTOR Laboratories, CA,
USA). Specimens were examined and photographed using a
ﬂuorescence microscope. Sections were counterstained with
Hoechst 33342 (Immunochemistry, MN, USA).
2.10. Statistical Analysis. Data were collected from three
independent experiments and analyzed with SPSS 12.0
software (SPSS Inc., IL, USA). Results were expressed as
mean ± SD, and P value < 0.05 was considered as statistical
signiﬁcance.
3. Results
3.1. Apamin Inhibits Expression of Proinﬂammatory Cytokine
and Adhesion Molecules. To investigate the eﬀect of apamin
on inﬂammatory response, this study assessed the eﬀect
of apamin on LPS-induced cytokine secretion in THP-
1-derived macrophages (Figure 1(a)). Expression levels of
proinﬂammatory cytokine were validated by an ELISA
kit. THP-1-derived macrophages expressed TNF-α after
exposure to LPS. Upregulation of TNF-α in LPS-treated
THP-1-derived macrophages was suppressed by apamin in
a concentration-dependent manner. Expression levels of
adhesion molecules, including VCAM-1 and ICAM-1, were
determined by western blot (Figure 1(b)). Protein levels of
VCAM-1 and ICAM-1 were higher in LPS-treated THP-1-
derivedmacrophagesthaninnormalcontrolcells.Treatment
with apamin resulted predominantly in the dose-dependent
downregulation of VCAM-1 and ICAM-1 expression levels4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: The eﬀect of apamin on expression levels of proinﬂammatory cytokine and adhesion molecules in LPS-treated THP-1-derived
macrophages. (a) Expression levels of TNF-α in culture supernatant, as determined by ELISA, signiﬁcantly inhibited by apamin in a dose-
dependent manner. (b) Expression levels of VCAM-1 and ICAM-1 were determined by western blot. They were decreased by apamin in a
dose-dependent manner. As a loading control, GAPDH was used to conﬁrm equal sample loading. ∗P<0.05 compared to control cells,
#P<0.05 compared to control cells treated with LPS alone.
in response to LPS. These results indicate that apamin eﬃ-
ciently discourages the activity of proinﬂammatory cytokine
and adhesion molecules in THP-1-derived macrophages.
3.2. Apamin Inhibits NF-κBA c t i v a t i o na n dN u c l e a rT r a n s l o -
cation of NF-κB. To determine the involvement of the IKK,
IκB, and NF-κB signaling pathways in the anti-inﬂammatory
property of apamin, activation of these three proteins was
examined by western blots of their dually phosphorylated
forms (Figure 2(a)). Upon LPS treatment, the total IKK
protein did not change from the cytosolic fractions, whereas
the phosphorylated IKK protein was particularly increased
when compared to the normal control. Addition of apamin
inhibited the LPS-induced phosphorylated IKK expression
level. Expression of IκB phosphorylation tended to increase
when treated with LPS. Addition of apamin reduced LPS-
induced IκB phosphorylation. In the nuclear fraction, phos-
phorylated NF-κB was also inhibited by apamin in a dose-
dependent manner. To determine whether the inhibitory
eﬀect of apamin on LPS-induced NF-κB activation was due
to inhibition of IκB phosphorylation and NF-κB translo-
cation, nuclear NF-κB p65 subunit levels were measured
following treatment with LPS in the presence and absence
of apamin. While LPS treatment increased nuclear NF-
κB p65, apamin cotreatment suppressed this translocation.
These results supported the explanation that apamin inhibits
NF-κB activation by suppression of IκB phosphorylation
at the transcription level in LPS-treated THP-1-derived
macrophages. After demonstrating that apamin decreased
NF-κB protein expression as measured by western blot,
the next experiment attempted to further examine the
eﬀect of apamin on transcriptional activity of NF-κBb y
EMSA. The DNA-binding activity of NF-κBn u c l e a rp r o -
tein was markedly higher in LPS-treated THP-1-derived
macrophages. LPS-induced NF-κB nuclear protein-DNA
binding activity was noticeably inhibited by apamin in a
dose-dependent manner (Figure 2(b)). To investigate the
transcriptional activity of NF-κB, expression of reporter
genes in cells transfected with plasmid NF-κB was ana-
lyzed. As shown in Figure 2(c), treatment of THP-1-derived
macrophages with LPS resulted in increased NF-κBa c t i v i t y
that was suppressed by apamin in a dose-dependent manner.
The results were consistent view that apamin inhibits the
expression of NF-κB, probably at the transcriptional level.
3.3. Apamin Reduces Lipid Levels, Ca2+Accumulation, and
TNF-α Expression of Serum. The eﬀects of apamin on serum
TC and TG levels were determined. After 12weeks of
feeding a high-fat diet and LPS treatment, mice developed
severe atherosclerosis with signiﬁcant elevation of serum
TC and TG levels, compared to the NC and Apa groups.
TC and TG levels were signiﬁcantly decreased by apamin
(Figures 3(a) and 3(b)). To conﬁrm that apamin aﬀected
Ca2+accumulation in atherosclerotic mice, Ca2+ accumula-
tion of serum was measured. As shown in Figure 3(c),C a 2+
accumulation was markedly enhanced in the LPS/fat group
compared to the NC and Apa groups. Ca2+ accumulation
was predominantly reduced in serum from apamin-treated
atherosclerotic mice compared to the LPS/fat group. The
expressionlevelofTNF-αwasmeasuredbyanELISAkit.The
NC and Apa groups did not display a signiﬁcant diﬀerence in
expression level of TNF-α (Figure 3(d)). Expression level of
TNF-α was elevated in the LPS/Fat group. In atherosclerotic
mice treated with apamin, expression level of TNF-α was
reduced compared to the LPS/Fat group.
3.4. Apamin Attenuates Formation of Atherosclerotic Lesions.
Pathological evaluations of aortic lesions were carried
out. Consecutive cross-sections of cuﬀed descending aortas
stained with H&E revealed induction of atheroscleroticEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: The eﬀe c to fa p a m i no nN F - κB signaling pathway in LPS-treated THP-1-derived macrophages. (a) Expression levels of IKK and
IκBα in the cytosolic fraction and NF-κB in the nuclear fraction were determined by western blot. GAPDH and histone H2B were used as
the internal controls for cytosolic and nuclear fraction loading control, respectively. (b) Nuclear NF-κB activity was examined by EMSA.
The arrow indicates the speciﬁc NF-κB band. (c) Luciferase activity was measured with a luminometer. ∗P<0.05 compared to control cells,
#P<0.05 compared to control cells treated with LPS alone.
lesion formation. The LPS/fatgroup showed a largernumber
of atherosclerotic lesions in the aorta compared to the NC
and Apa groups (Figure 4(a)). In the LPS/fat group, nearly
all animals developed fatty streaks in the aortic arch, with
accumulation of lipids localized mainly in areas subjacent to
the endothelium. Compared to the LPS/fat group, treatment
with apamin changed the size of atherosclerotic lesions in
aortas suggesting that apamin exerted apparent protective
atherogenic actions. These inhibitory eﬀects of apamin on
atherosclerotic mice were markedly displayed among the
four groups when entire aortas were stained by elastic stain
(Figure 4(b)). In atherosclerotic mice treated with apamin,
atheroscleroticlesionsweresigniﬁcantlydecreasedcompared
to the LPS/fat group. This result was consistent with H&E
stain analysis.
3.5. Apamin Attenuates Expression Levels of Adhesion
Molecules and Fibrotic Factors. Protein and mRNA levels of
adhesion molecules (VCAM-1 and ICAM-1) and ﬁbrotic
factors (TGF-β1 and ﬁbronectin) after apamin treatment in
atherosclerotic mice were detected by western blot and RT-
PCR, respectively. As shown in Figure 5(a), aortas from the
NC, and Apa groups showed little expression of VCAM-1
and ICAM-1. However, a more signiﬁcant upregulation of
these expression levels was observed in the LPS/Fat group,
while treatment with apamin led to evident downregulation
of VCAM-1 and ICAM-1 expression levels. Similarly, expres-
sion levels of TGF-β1 and ﬁbronectin were decreased in the
aorta of the LPS/fat+Apa group compared to LPS/fat group.
Moreover, expression levels of ICAM-1 in atherosclerotic
lesions were determined by immunohistochemical staining.
As shown in Figure 5(b), ICAM-1 expression levels were
barely detected in aortic sections from the NC and Apa
groups. Suppressed expression levels in surface area lesions
revealed that apamin inhibited ICAM-1 expression levels in
atherosclerotic lesions, which agreed with the results from
current in vitro experiment. These results indicated that
apamin suppresses the expression of VCAM-1, ICAM-1,
TGF-β1, and ﬁbronectin in atherosclerotic mice.
3.6. Apamin Reduces Inﬁltration of Macrophages. To investi-
gate whether apamin could inﬂuence atherosclerotic lesions,
aortas of experimental mice were collected for immunohis-
tochemistry. Greater macrophage inﬁltrations in atheroscle-
rotic mice were demonstrated using F4/80, a speciﬁc marker
of macrophages (Figure 6(a)). Atherosclerotic lesions in6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The eﬀect of apamin on biochemical parameters in atherosclerotic mice. Total cholesterol (a), triglycerides (b), and Ca2+
accumulation (c) were measured using a commercial kit. Expression level of TNF-α (d) was determined by ELISA. ∗P<0.05 compared
to normal control, #P<0.05 compared to atherosclerotic mice.
(a) (b)
Figure 4: Histological cross-sections of descending aorta in atherosclerotic mice. (a) H&E staining and (b) elastic staining showed that
atherosclerotic changes were attenuated in the LPS/Fat+Apa group by apamin. NC, normal control; Apa, normal control treated with
apamin; LPS/Fat, LPS injection and high fat dieted mice (atherosclerotic mice); LPS/Fat+Apa, atherosclerotic mice treated with apamin.
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Figure 5: The eﬀect of apamin on expression levels of VCAM-1, ICAM-1, TGF-β1, and ﬁbronectin in atherosclerotic mice. (a) Western blot
(left panel) and RT-PCR (right panel) suppressed expression levels of those protein by apamin. As a loading control, GAPDH was used to
conﬁrm equal sample loading. (b) Immunohistochemistry of ICAM-1 predominantly attenuated in the LPS/fat+Apa group. NC, normal
control; Apa, normal control treated with apamin; LPS/fat, LPS injection and high-fat-dieted mice (atherosclerotic mice); LPS/fat+Apa,
atherosclerotic mice treated with apamin. Scale bars, 50μm.
(a) (b)
Figure 6:Theeﬀectofapaminonmacrophageinﬁltrationsinatheroscleroticmice.(a)Immunohistochemistryand(b)immunoﬂuorescence
examinations showed that apamin markedly inhibited macrophages inﬁltration in atherosclerotic mice. Micrographs display macrophages
(green), nuclei (blue), and merged images. NC, normal control; Apa, normal control treated with apamin; LPS/Fat, LPS injection and high-
fat-dieted mice (atherosclerotic mice); LPS/Fat+Apa, atherosclerotic mice treated with apamin. Scale bars, 50μm.
atherosclerotic mice treated with apamin showed decreased
inﬁltration of macrophages into the arterial wall. F4/80
positive areas in the mice treated with apamin were signif-
icantly reduced to the total cross-sectional area of aortas
compared to the LPS/fat group. Similarly, macrophages inﬁl-
tration of atherosclerotic lesions was markedly attenuated
by apamin, as determined by immunoﬂuorescence staining
(Figure 6(b)). Taken together, these results indicate that
apamin treatment substantially attenuates atherosclerotic
lesions.
4. Discussion
Atherosclerosis is increasingly recognized as a chronic
inﬂammatory disease. It is a multifactorial and progressive8 Evidence-Based Complementary and Alternative Medicine
disease in which inﬂammatory reaction and inﬂammation-
related mediators play pivotal roles at all stages [17].
Various research studies of the anti-inﬂammatory eﬀect
of BV have recently been conducted [18–20]. Studies
of the general pharmacological proﬁles of BV and its
components have also been conducted [13, 21]. Apamin
comprises 2-3% of the dry weight of apamin [22]. BV has
been reported as having proinﬂammatory [23]a n da n t i -
inﬂammatoryeﬀects[18].Anumberofstudieshavereported
on a variety of mechanisms for the anti-inﬂammatory
eﬀect of BV and its constituents [13, 19, 22]. An anti-
inﬂammatory eﬀect of apamin accompanied by a reduction
of seromucoid and haptoglobin levels has been reported
[22].
In this study, apamin suppressed LPS-induced THP-
1-derived macrophage inﬂammation via the NF-κB signal
pathway. Furthermore, in atherosclerotic mice, apamin
attenuated the regulation of various atherosclerotic factors
by inhibiting inﬂammation.
Inﬂammation is pivotal to atherosclerosis, and mono-
cytes/macrophages are critical participants. Monocytes/ma-
crophages secrete IL-6, IL-1β,a n dT N F - α, and the serum
concentrations of several markers of inﬂammation are
associated with future cardiovascular risk [24]. This study
used an in vitro cell-based system using THP-1-derived
macrophages with LPS stimulation to test the anti-
inﬂammatory eﬀect of apamin. Apamin treatment signif-
icantly decreased TNF-α expression level in LPS-induced
THP-1-derived macrophages. Adhesion molecules also play
important roles in cellular interactions during inﬂammatory
responses. Expression of VCAM-1 and ICAM-1 may inﬂu-
ence the organization of cells that promote the production
of cytokines in inﬂammatory cells [3]. Our data proves that
LPS stimulation promotes the expression of these adhesion
molecules in THP-1-derived macrophages. The expression
levels of VCAM-1 and ICAM-1 were predominantly reduced
in a dose-dependent manner after treatment with apamin in
mice.
A role for activation of the NF-κB in regulation of
inﬂammatory responses was reported [25]. NF-κBa c t i v a -
tion by TNF-α is required for transcription of the gene
encoding cell adhesion molecules [26]. Following exposure
of macrophages to LPS, NF-κB is activated by phosphory-
lation and degradation of IκB. The activated NF-κBw a s
then translocated into the nucleus, leading to transcrip-
tional expression of genes associated with inﬂammatory
responses [27]. In the current study, apamin suppressed
LPS-inducible IκB phosphorylation and nuclear NF-κBp 6 5
activation in a concentration-dependent manner in THP-
1-derived macrophages. These results demonstrate that
apamin mediated an anti-inﬂammatory eﬀect via the NF-
κB signaling system. More data is required to determine
whether the potential diﬀerential eﬀect of apamin occurs
upstream of NF-κB and particularly upstream of IKK based
on current results that apamin inhibited phosphorylation
of IKK in a dose-dependent manner in THP-1-derived
macrophages.
Based on these in vitro results, the eﬀect of apamin
in an animal model of atherosclerosis was investigated.
Atherosclerosis can be induced in mice given LPS injection
and fed a high-fat diet [20, 28]. Accumulation of cholesterol
and lipids resulting in foam cell formation is regarded as a
critical process in the development of atherosclerosis. Pro-
gressivelipidaccumulationleadstoincreasesinexpressionof
proinﬂammatory cytokines and inﬁltration of inﬂammatory
cells [29]. Proinﬂammatory cytokines have been reported
to promote eﬄux of cholesterol [30]. Stimulation of the
mechanism involved in decrease of lipids and cholesterol
in macrophages may thus be an eﬀective way to prevent
atherosclerosis. Our results from treatment with apamin
showed that serum TC and TG levels were signiﬁcantly
decreased in the atherosclerotic mice. Studies have demon-
strated that modiﬁcation of lipid can induce Ca2+ inﬂux,
that Ca2+ is closely associated with production of TNF-α
involved in the inﬂammatory response, and that inhibition
of the inﬂux of Ca2+ might attenuate these responses
[31, 32]. In this study, apamin signiﬁcantly reduced Ca2+
accumulation. In addition, TNF-α level decreased in the
serum of atherosclerotic mice following apamin treatment.
These data suggest that the anti-atheroscleortic eﬀects of
apamin may occur via inhibition of Ca2+ accumulation and
proinﬂammatory cytokines.
Expression levels of VCAM-1 and ICAM-1 were largely
studied in a mouse model of atherosclerosis [33], and
these molecules were upregulated by a high-cholesterol diet
in an animal model [34]. Presently, protein and mRNA
levels of these adhesion molecule expressions were predomi-
nantly decreased by apamin in atherosclerotic mice. Further,
atherosclerotic lesion development was accompanied by
upregulation of ICAM-1. This is consistent with other
studies that reported that a high-fat diet induces both
lesion development and expression of adhesion molecules
in general [33, 34] .T r e a t m e n tw i t ha p a m i na t t e n u a t e db o t h
lesion development and adhesion molecule expressions in
atherosclerotic mice.
TGF-β1 expression is upregulated in plaque develop-
ment and appears to be involved in atherosclerotic lesions
under a variety of circumstances which is further related
to extracellular matrix remodeling [35]. The extracellular
matrix protein ﬁbronectin is focally deposited in atheroscle-
rosis where it contributes to inﬂammatory signaling [36].
Several studies have reported that monocyte binding to
ﬁbronectin causes the induction of potent proinﬂamma-
tory cytokines, together with the ability of ﬁbronectin
to promote NF-κBa c t i v a t i o n[ 36, 37]. In the present
study, protein and mRNA levels of TGF-β1 and ﬁbronectin
expression were inhibited by apamin in atherosclerotic
mice.
Inﬁltration and activation of monocytes into the arterial
walls are critical steps in atherogenesis [38]. Macrophages
accumulate cholesterol and lipids, resulting in foam cell
formation, which is considered a critical process in devel-
opment of atherosclerosis [39]. We were able to witness
the macrophage inﬁltration via western blot (data not
shown), immunohistochemistry, and immunoﬂuoresence
staining. However, macrophage inﬁltration was signiﬁcantly
reduced by apamin in the aorta from atherosclerotic
mice.Evidence-Based Complementary and Alternative Medicine 9
5. Conclusion
Treatment with apamin in THP-1-derived macrophages
suppresses inﬂammatory responses by a decrease of the NF-
κB signal pathway. Furthermore, atherosclerotic mice treated
with apamin predominantly attenuate lipids, Ca2+ levels,
proinﬂammatory cytokines, adhesion molecules, ﬁbrotic
factors, and macrophage inﬁltration. These mechanisms
couldbeinvolvedinthepossibleroleofapamininprotection
against atherosclerosis. Therefore, apamin may be a thera-
peutically useful agent for use in atherosclerosis prevention.
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